Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,180,485 papers from all fields of science
Search
Sign In
Create Free Account
SM 13496
Known as:
SM13496
, SM-13496
, 13496, SM
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Lurasidone Hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496).
C. Hopkins
ACS Chemical Neuroscience
2011
Corpus ID: 30568993
S chizophrenia is a chronic and extremely severe disorder of the mind and brain that affects approximately 1% of the population…
Expand
Highly Cited
2010
Highly Cited
2010
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
T. Ishibashi
,
T. Horisawa
,
+13 authors
Mitsutaka Nakamura
Journal of Pharmacology and Experimental…
2010
Corpus ID: 12893717
Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano…
Expand
Highly Cited
2007
Highly Cited
2007
Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
T. Ishiyama
,
K. Tokuda
,
T. Ishibashi
,
Akira Ito
,
Satoko Toma
,
Y. Ohno
European Journal of Pharmacology
2007
Corpus ID: 19040520
1999
1999
In vitro binding profile of SM-13496, a novel atypical antipsychotic agent
K. Yabuuchi
,
T. Horisawa
,
T. Ishibashi
,
Y. Ohno
1999
Corpus ID: 90794453
1997
1997
Behavioral characteristics of SM-13496, a novel atypical antipsychotic agent
Y. Ohno
,
T. Ishibashi
,
+6 authors
M. Nakamura
1997
Corpus ID: 147819528
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE